Comparison of the Immunogenicity of ChAdOx1 nCoV-19 (COVID-19) Vaccine against the Wild-Type and Delta Variant in Kidney Transplant Recipients and Healthy Volunteers
Recruiting
- Conditions
- Immune response after ChAdOx1 nCoV-19 Vaccine in kidney transplant patients compared to healthy volunteers.Immune response, ChAdOx1 nCoV-19 Vaccine, kidney transplant patients, Wuhan Strain, B.1.617.2 (Delta) Variant, antibody, T-cell response
- Registration Number
- TCTR20211025004
- Lead Sponsor
- Kao Tun Roke Foundation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
1. Adult (age >= 18 years old), 2.Kidney transplant recipients, 3. Recipients 2 doses of ChAdOx1 nCoV-19 vaccine
Exclusion Criteria
1. Refuse to participate, 2.Infected with COVID-19 during the study period, 3. Recipients of intravenous immunoglobulin
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Immunogenicity 2-6 weeks after vaccination Antibody response and T-cell response
- Secondary Outcome Measures
Name Time Method Associated factors of antibody response After the results of immune response Statistical analysis,Associated factors of T-cell response After the results of immune response Statistical analysis,Safety and adverse reactions after vaccination After completion of each dose of vaccination Statistical analysis